Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2001

View Archived Issues

New class of compounds found active against hepatitis C

NIH awards Antigenics grant to support development of malaria vaccine

Vasogen commences chronic lymphocytic leukemia clinical trial in Canada

Milestone payment received by Adolor from GSK for dermal ADL-2-1294

Epothilone B derivative CGP-85715 characterized in vitro and in vivo

PNU-252808 associated with blockade of cell cycle progression and induction of apoptosis

Cardioprotective effects of new antioxidant discussed at Kyoto meeting

Genetronics reports promising results from phase II trials of EPT technology

E.C. approves Novartis's Starlix for type 2 diabetes

Novel probes for the dopamine transporter designed at NIDA

Atrix grants European marketing rights for Leuprogel to MediGene

DuPont describes efforts to design improved antipsychotic agents

Ortho-Clinical Diagnostics and Caprion to develop blood test for vCJD

SR-374: a new DuPont compound with potent and selective anti-factor Xa activity

Different doses of toborinone evaluated for electrophysiological effects in dogs

Efficacy and lack of CNS adverse effects reported for Adolor analgesic

Preclinical study results for JTV-519 discussed in Kyoto

InKine awarded NIH grant to support angiogenesis inhibitor research

Japanese approval of Zyvox marks achievement of regulatory milestone

Axonyx's phenserine regulates APP processing in preclinical study

Multiprotein AIDS vaccine provides high-level protection in monkeys, advances toward human trials

Inhibitors of MTP and their potential uses described by Boehringer Ingelheim

New serotonergic compounds described as particularly useful for depression, memory disorders

Bertek licenses beta-blocker nebivolol; new indications to be evaluated

Merck presents new group of integrin antagonists in recent patent

Bicyclic RAR agonists from Roche described as useful for emphysema and related disorders

Pfizer reports hydroxamic acid-based selective aggrecanase inhibitors

Canadian-Japanese team discovers new cytokine inhibitors

Inhibitors of NO production claimed for MS, RA, CHF and dilated cardiomyopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...